REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.

Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to ...

Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated ...

A young nurse and mother initially thought the red spot on her tongue was the physical toll of a bad breakup, but the reality ...

Roche said its $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

More ICE detainees died in custody in 2025 than in any year in at least two decades, and 2026 is on track to be even higher.

When saliva becomes stagnant or overly concentrated, these minerals crystallise, forming a stone that can block the narrow ...

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand ...

The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today ...